目的 探討活血止痛膠囊聯(lián)合骨肽注射液治療膝骨性關(guān)節(jié)炎的臨床療效。方法 選取2015年1月-2016年1月在內(nèi)江市第一人民醫(yī)院骨科接受治療的膝骨性關(guān)節(jié)炎患者78例,根據(jù)治療方案的不同分為對(duì)照組(39例)和治療組(39例),對(duì)照組關(guān)節(jié)腔注射骨肽注射液,30 mg/次,1次/周;治療組在此基礎(chǔ)上口服活血止痛膠囊,6粒/次,2次/d。兩組患者均連續(xù)治療4周。比較兩組患者治療前后總有效率。觀察兩組治療前后Lequesne指數(shù)和視覺模擬分?jǐn)?shù)變化情況,同時(shí)檢測(cè)兩組治療前后血清IL-1β、TNF-α、MMP-9和NO水平改變。結(jié)果 治療后,對(duì)照組和治療組總有效率分別為79.49%和94.87%,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療后,兩組患者Lequesne指數(shù)和視覺模擬分?jǐn)?shù)均明顯降低(P<0.05),但治療組降低的更明顯,兩組比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療后,兩組患者血清IL-1β、TNF-α、MMP-9和NO水平均明顯降低(P<0.05),但治療組降低的更明顯,兩組比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論 活血止痛膠囊聯(lián)合骨肽注射液治療膝骨性關(guān)節(jié)炎療效顯著,可明顯改善患者膝關(guān)節(jié)功能和減輕關(guān)節(jié)疼痛及降低血清炎性因子水平,具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To observe the clinical effects of amisulpride combined with olanzapine in improvement of cognitive function in patients with schizophrenia. Methods Patients (61 cases) with schizophrenia in Mental Health Center of Baoshan District in Shanghai from October 2013 to October 2015 were randomly divided into control group (31 cases) and treatment group (30 cases). The patients in the control group were po administered with Olanzapine Tablets 10 mg/d at beginning, then gradually added to 15 - 20 mg/d according to patient's condition and symptoms in one week, and the average dosage was (18.75 ± 1.13) mg/d. Patients in the treatment group were po administered with Amisulpride Tablets 0.1 g/d at beginning, then gradually added to 0.1 - 0.3 g/d according to patient's condition in one week, and the average dosage was (0.26 ± 0.06) mg/d. Two groups were treated for 8 weeks. Positive and negative syndrome scale (PANSS), Wechsler memory scale (WMS), and Wisconsin card sorting test (WCST) were compared before and after treatment. Results After treatment for 4 weeks, positive symptom scores, general mental pathological symptom scores, and total scores in both groups were improved significantly (P < 0.05, 0.01). The negative symptom scores and total scores in the treatment group were significantly better than those in the control group, and there were significant differences between two groups (P < 0.05). After treatment for 8 weeks, positive symptom scores, negative symptom scores, general mental pathological symptom scores, and total scores in both groups were improved significantly, and the differences were statistically significant in the same group (P < 0.05). There was no significant difference between two groups. After treatment for 8 weeks, the number of correct responses and categories were significantly increased, but the number of random errors was significantly decreased, and the differences were statistically significant in the same group (P < 0.05). The WCST scores in the treatment group were significantly better than those in the control group, and there were significant differences between two groups (P < 0.05). After treatment for 8 weeks, there was no significant difference between two groups. Conclusion Amisulpride combined with olanzapine has significant clinical curative effect in improvement of cognitive function in patients with schizophrenia, which has a certain clinical application value.